HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Cements Supplement Sales Gains From Initial COVID Boost

Executive Summary

A year on from the start of the COVID-19 outbreak and a global rush for supplements, Bayer has cemented these sales gains with slight growth at its Nutritionals business in Q1.

You may also be interested in...



OTC Allergy Switch Approved For Bayer In US

CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.

Bayer Consumer Health Looks To India And China For New Sources Of Growth

Bayer Consumer Health is stepping up investments in India, China and South East Asia to unleash untapped potential in these high growth OTC markets. 

Demand For Supplements Helps Bayer Outpace Global Market In 2020

Enjoying a 5% sales rise, Bayer Consumer Health grew faster than the global market last year, with the company keen to repeat the performance in 2021.

Related Content

Topics

UsernamePublicRestriction

Register

RS151323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel